Low vitamin D in patients with nasal polyps negatively correlated with several markers, including Lund-Mackay and total nasal ...
The studies evaluated the safety and efficacy of depemokimab versus placebo in adults with CRSwNP, a chronic condition affecting millions globally. The study's co-primary endpoints were to see the ...
AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...
Hosted on MSN1mon
Celltrion's asthma treatment greenlit for Canadian releaseCRSwNP is a long-term condition wherein sinuses are inflamed, and small, noncancerous lumps called nasal polyps form within a patient's nose, making it difficult to breathe, smell or taste.
GlobalData on MSN19d
China’s NMPA approves GSK’s Nucala for CRSwNP treatmentThe China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...
A 2023 article notes that they most commonly develop in those with chronic rhinosinusitis, which has resulted in the term chronic rhinosinusitis with nasal polyposis (CRSwNP). Other associations ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback